“We see a strong momentum with increasing interest from collaboration partners which already has resulted in two new products available for tender participation. In addition, we continue making advancement of our pipeline with regulatory submissions and approvals.”
–
Quarter 1,
· Net revenue was 258 (0) tkr.
· EBITDA was -5 442 (-3 553) tkr.
· Operating cash flow was -5 215 (-4 744) tkr.
· Cash position in the end of period was 27 393 (7 682) tkr.
· Licensed products at the end of period were 30 (17).
· Products with distribution rights at the end of the period were 2 (0).
· Products with marketing authorization in the end of the period were 7 (0).
Significant events during the quarter
·
· Winning a tender for Sunitinib in
· Teriflunomide Newbury approved by the Norwegian Health Authorities.
· Expands its portfolio with two ready to launch products, Daptomycin and Linezolid with already granted Marketing Authorizations (MA) in
Significant events after the end of the quarter
· Fampridine Newbury approved by the Swedish Health Authorities.
· Redeye initiated coverage of
· Announcement of sales orders confirmed for international markets totalling app. 6.2 MSEK during 2023.
· Withdrawal of Gabapentin marketing application due to increased regulatory requirements.
A word from the CEO
This Quarter was characterized by a high level of business development initiatives and making further progress on advancing our portfolio with regulatory approvals.
Business development:
We successfully participated at the most important annual congress called CPHI in
We have signed two partnerships granting us access to two already approved products in
Commercialization:
Sales in this Quarter was isolated to winning the tender for Icatibant Newbury in
Furthermore, our international sales activities have generated sales orders for shipments during 2023 totalling app 6.2 MSEK.
Regulatory approvals:
We have obtained approval of Teriflunomide and Fampridine during the recent months. With the addition of two new products with already-granted marketing approvals, we now have 8 products approved across Scandinavia.
By the end of
There are many on-going regulatory procedures across Scandinavia for our portfolio and several new approvals are expected during 2023.
Finally, I wish readers and investors a happy new year. It has been a pleasure to meet many of you during recent investor events in
© Modular Finance, source